Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?
Approach ┬╖ directive: тАЬwhy / howтАЭ
What it asks ┬╖ Explain why biotechnology has grown so fast in India (skills, policy, demand) and how that has helped biopharma: vaccines, biosimilars and low-cost drugs.
It asks 2 things тАФ answer each
- Why: reasons for the high level of biotechnology activity in India, with its drivers (talent, industry base, demand, policy, biodiversity, IPR)
- How: how this activity has benefited biopharma (vaccines, biosimilars, missions, diagnostics), with the remaining challenges and the way forward
Open with ┬╖ India's bioeconomy grew from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, about 4.25 per cent of GDP (DBT, 2025), and biopharma is 35 per cent of it; this activity has causes, and biopharma is its clearest beneficiary.
Cover
- Drivers: a large pool of trained scientists and low-cost research, rich biodiversity, an established generic pharma industry, and big needs in health, food and energy.
- Policy push: the Department of Biotechnology (1986), the National Biotechnology Development Strategy (2015-20), BIRAC (2012) for start-ups and industry, incubators and biotech parks, and Make in India.
- Farm and industrial biotech: Bt cotton since 2002, biofertilisers and biopesticides, tissue culture, enzymes and biofuels, though the debate on genetically modified crops continues.
- Biopharma gains: India is a leading vaccine maker; indigenous vaccines such as Rotavac, affordable insulin, monoclonal antibodies, biosimilars and diagnostics lower prices and support exports.
- Regulation and IPR: product patents since 2005 pushed firms towards innovation; guidelines on similar biologics (2012, revised 2016) opened the biosimilar route.
- Challenges: thin early-stage funding, slow approvals, imported inputs and equipment, weak translational research, biosafety and the ethics of clinical trials.
Close with ┬╖ With a US$ 300 billion bioeconomy targeted for 2030, India must convert vaccine-scale manufacturing into discovery-led biopharma, making affordable biologics a pillar of Atmanirbhar Bharat.
Add value (verified)
- India BioEconomy Report 2025 (DBT/BIRAC, PIB): the bioeconomy grew from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, with a US$ 300 billion target for 2030; it contributes 4.25 per cent of GDP with a CAGR of 17.9 per cent over four years.PIB backgrounder: The Rise of India's Bioeconomy, from $10bn to $165.75bn in a decade (27 March 2025) тЖЧтАЬIndia's bioeconomy has grown from $10 billion in 2014 to $165.7 billion in 2024, with a target of $300 billion by 2030. тАв The sector contributes 4.25% to GDP with a compound annual growth rate (CAGR) of 17.9% over the past four years.тАЭ
- The National Biopharma Mission, co-funded with the World Bank (US$ 250 million), supports over 100 projects and 30 MSMEs; India is among the top vaccine producers and developed the world's first DNA COVID-19 vaccine.PIB backgrounder: The Rise of India's Bioeconomy (27 March 2025) тЖЧтАЬThe National Biopharma Mission, co-funded with the World Bank ($250 million), supports over 100 projects and 30 MSMEs. тАв India is among the top producers of vaccines globally and developed the worldтАЩs first DNA COVID- 19 vaccine.тАЭ
- The BioE3 Policy (Biotechnology for Economy, Environment and Employment) was approved by the Union Cabinet on 24 August 2024.PIB backgrounder: The Rise of India's Bioeconomy (27 March 2025) тЖЧтАЬBioE3 (Biotechnology for Economy, Environment and Employment) Policy marks a significant leap in IndiaтАЩs biotechnology sector. Approved by the Union Cabinet on 24th August 2024тАЭ
- The bioeconomy's subsectors: BioIndustrial 47 per cent, BioPharma 35 per cent, BioAgri 8 per cent and BioResearch 9 per cent; BioE3 plans biomanufacturing and Bio-AI hubs and a biofoundry.PIB backgrounder: The Rise of India's Bioeconomy (27 March 2025) тЖЧтАЬBiomanufacturing & Bio-AI hubs and BiofoundryтАЭ
Question: UPSC's CS (Main) 2018, GS Paper III тАФ paper тЖЧ. Approach: Minimalist IAS, checked 3 Oct 2026 (how we verify) тАФ UPSC publishes no model answers. ┬╖
Model answer┬╖ 364words ┬╖ Minimalist IAS
India's bioeconomy grew from US$ 10 billion in 2014 to US$ 165.7 billion in 2024, about 4.25 per cent of GDP (DBT, 2025); biopharma alone is 35 per cent of it. Such activity has causes, and biopharma is its clearest beneficiary.
Why there is so much biotechnology activity
- Talent and cost: a large pool of biologists, chemists and engineers, and research at a fraction of Western cost.
- Generic pharma base: an established pharmaceutical industry with manufacturing scale and regulatory experience, ready to move into biologics.
- Demand: a heavy disease burden, affordable vaccines and drugs, food security and biofuels create domestic markets.
- Policy architecture: the Department of Biotechnology (1986), the National Biotechnology Development Strategy 2015-20, BIRAC (2012) funding start-ups and industry-academia projects, biotech parks and Make in India; since then, the BioE3 Policy (Cabinet, 24 August 2024) adds biomanufacturing hubs and a biofoundry.
- Biodiversity and farm use: rich genetic resources; Bt cotton since 2002, biofertilisers, biopesticides and tissue culture, though the GM food-crop debate continues.
- IPR: product patents since 2005 pushed firms from copying towards innovation.
Drivers of India's biotech boom: Scientific talent; Generic pharma base; Health and food demand; DBT-BIRAC policy; Biodiversity; Product patents
How this activity has benefited biopharma
- Vaccines: India is among the world's top vaccine producers; indigenous Rotavac showed research-to-market capability, and India made the world's first DNA COVID-19 vaccine.
- Biosimilars: guidelines on similar biologics (2012, revised 2016) opened a regulated path; Indian firms make affordable insulin and monoclonal antibodies, cutting prices at home and building exports.
- Mission support: the National Biopharma Mission (Innovate in India), co-funded with the World Bank at US$ 250 million, supports over 100 projects and 30 MSMEs.
- Diagnostics and start-ups: low-cost diagnostic kits and industrial enzymes widen access; BIRAC grants and incubators feed a start-up pipeline.
Challenges that remain
- Gaps: thin early-stage funding, slow approvals, imported inputs and equipment, weak translational research, and biosafety and clinical-trial ethics.
Way forward
- Scale and trust: predictable single-window regulation, BioE3's biomanufacturing and Bio-AI hubs, and public money for translational research and biosafety capacity.
With a US$ 300 billion bioeconomy targeted for 2030, India's task is to convert vaccine-scale manufacturing into discovery-led biopharma, making affordable biologics a pillar of Atmanirbhar Bharat.
Prepared by Minimalist IAS to the answer standard of Shivam Singh (mentor, 7 years) ┬╖ facts checked against official sources (how we verify) ┬╖ updated 3 Oct 2026. UPSC publishes no model answers: compare your structure and coverage with this, then write your own.
